Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Growth Paris
02/25/2021 02/26/2021 03/01/2021 03/02/2021 03/03/2021 Date
17.94(c) 17.8(c) 18.82(c) 18.62(c) 17.92(c) Last
150 906 403 217 137 246 87 552 120 342 Volume
-3.76% -0.78% +5.73% -1.06% -3.76% Change
More quotes
Financials
Sales 2020 57,2 M 68,9 M 68,9 M
Net income 2020 -76,7 M -92,5 M -92,5 M
Net cash position 2020 157 M 189 M 189 M
P/E ratio 2020 -6,01x
Yield 2020 -
Sales 2021 66,5 M 80,1 M 80,1 M
Net income 2021 -107 M -129 M -129 M
Net cash position 2021 51,7 M 62,3 M 62,3 M
P/E ratio 2021 -6,34x
Yield 2021 -
Capitalization 771 M 931 M 930 M
EV / Sales 2020 10,7x
EV / Sales 2021 10,8x
Nbr of Employees 259
Free-Float 83,2%
More Financials
Company
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and... 
More about the company
Notations Surperformance© of Cellectis
Trading Rating : Investor Rating :
More Ratings
All news about CELLECTIS
03/01European ADRs Move Lower on Monday's Trading
MT
02/25CELLECTIS TO HOLD FOURTH QUARTER 202 : 00am est
GL
02/23European ADRs Move Slightly Higher in Tuesday Trading
MT
02/19CALYXT, INC.  : Change in Directors or Principal Officers, Regulation FD Disclos..
AQ
02/18European ADRs Move Sharply Lower in Thursday Trading
MT
02/17European ADRs Move Lower in Wednesday Trading
MT
02/16European ADRs Move Sharply Higher in Tuesday Trading
MT
02/16CELLECTIS S A  : Cytovia Team Up to Develop Gene-Edited Natural Killer Cells
MT
02/16CELLECTIS  : Up 7% After Entering $760 Million Strategic Collaboration With Cyto..
MT
02/16CELLECTIS  : Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-E..
AQ
02/16Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC..
GL
02/08European ADRs Move Higher in Monday Trading
MT
02/04European ADRs Nudge Lower in Thursday Trading
MT
02/03European ADRs Nudge Higher in Wednesday Trading
MT
01/31CELLECTIS  : Monthly statement on outstanding equity shares and voting rights
CO
More news
News in other languages on CELLECTIS
02/25Cellectis organise une conférence téléphonique pour présenter ses résultats f..
2020Une dernière soirée avec la Fed
2020EN DIRECT DES MARCHES  : Atos, Crédit Agricole, Eramet, Valneva, Nanobiotix, Goo..
2020CELLECTIS  : la FDA autorise la reprise de l'essai clinique MELANI-01
2020Les marchés attendent leur shoot de vaccin et de liquidités
More news
Stock Trading Strategies
CELLECTIS - 2020
Is the distribution phase coming to an end ?
BUY
More Stock Trading Analysis
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 27,35 €
Last Close Price 17,92 €
Spread / Highest target 62,9%
Spread / Average Target 52,6%
Spread / Lowest Target 42,3%
EPS Revisions
Managers and Directors
NameTitle
André Choulika Chief Executive Officer
Eric Dutang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS-26.56%967
MODERNA, INC.40.53%58 690
LONZA GROUP AG1.62%46 935
IQVIA HOLDINGS INC.6.37%36 961
CELLTRION, INC.-15.60%35 341
SEAGEN INC.-15.54%27 847